Want to join the conversation?
$MRK, which competes with rivals $GSK and $PFE, said the company's human health and animal health businesses performed well in 2Q16, delivering growth despite an approx. $210MM headwind in sales in Venezuela in 2Q15. The company said it expects adjusted OpEx for the full year to be generally in line with the prior year.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.